Atara Biotherapeutics, Inc.
ATRA
$10.51
$0.292.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 516.00K | 1.60M | 3.45M | 17.58M | 98.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 516.00K | 1.60M | 3.45M | 17.58M | 98.15M |
| Cost of Revenue | 288.00K | 783.00K | 3.03M | 6.92M | 39.52M |
| Gross Profit | 228.00K | 812.00K | 428.00K | 10.66M | 58.63M |
| SG&A Expenses | 3.60M | 3.37M | 3.98M | 5.94M | 10.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.89M | 7.01M | 7.00M | 12.86M | 49.53M |
| Operating Income | -3.37M | -5.42M | -3.55M | 4.72M | 48.62M |
| Income Before Tax | -4.15M | -3.41M | -4.28M | 2.39M | 38.01M |
| Income Tax Expenses | -- | 0.00 | 28.00K | 3.00K | -- |
| Earnings from Continuing Operations | -4.15M | -3.41M | -4.30M | 2.39M | 38.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.15M | -3.41M | -4.30M | 2.39M | 38.01M |
| EBIT | -3.37M | -5.42M | -3.55M | 4.72M | 48.62M |
| EBITDA | -3.34M | -4.37M | -3.19M | 5.62M | 50.41M |
| EPS Basic | -0.29 | -0.25 | -0.32 | 0.20 | 3.53 |
| Normalized Basic EPS | -0.18 | -0.29 | -0.20 | 0.20 | 2.78 |
| EPS Diluted | -0.29 | -0.25 | -0.32 | 0.19 | 3.50 |
| Normalized Diluted EPS | -0.18 | -0.29 | -0.20 | 0.20 | 2.75 |
| Average Basic Shares Outstanding | 14.08M | 13.62M | 13.56M | 12.20M | 10.76M |
| Average Diluted Shares Outstanding | 14.08M | 13.62M | 13.56M | 12.31M | 10.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |